In October 2010, Adeona announced that Part 2 of its randomized, double-blind, placebo-controlled CooperProof-2 clinical research evaluating Zinthionein, a new zinc-centered treatment for Alzheimer’s disease, finished 100 percent patient enrollment. Individuals are assessed 3 and 6 months after they begin the once-daily oral medication or matching placebo, and all patients should complete their 6 month treatment by the finish of March 2011. It is anticipated that the medical study results ought to be available shortly thereafter. To day, there were no significant undesireable effects reported.These results differ partly from those of a post hoc evaluation of data from the BCIRG 001 trial carried out by Hugh et al.,23 who found an advantage for TAC among individuals with HER2-positive tumors. However, this inconsistency may be irrelevant because standard practice today for women with HER2-positive early-stage breast cancers is normally treatment with adjuvant chemotherapy plus trastuzumab.24 Hugh and colleagues, like our investigators, discovered that patients with triple-bad tumors had improved disease-free survival when treated with TAC.